Palvella Therapeutics, Inc. Gain (Loss) on Extinguishment of Debt
Palvella Therapeutics, Inc. (PVLA) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2025-03-31
- Palvella Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Palvella Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2023 was $23.10M.
| Period end | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-31 |
| 2023-12-31 | $23.10M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |